Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of hepatitis C drug developer Inhibitex
So what: Last month, rival Pharmasset
Now what: McMinn said that there could be a lot of downside if safety issues arise, although she believes the risk-reward balance is still positive. Inhibitex is conducting a study to evaluate different dosages, and the interim results of the study are expected within this month or next. Shareholders are anxious that INX-189 may share too many similarities with Pharmasset's PSI-938.
Interested in more info on Inhibitex? Add it to your watchlist.
Fool contributor Evan Niu holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Bank of America. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.